NCT02903914 - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

September 14, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

August 15, 2022

Conditions

Metastatic CancerSolid TumorsColorectal Cancer (CRC)Gastric CancerHead and Neck CancerLung CancerRenal Cell Carcinoma (RCC)Bladder CancerUC (Urothelial Cancer)Mesothelioma

Interventions

DRUG

INCB001158

Arginase Inhibitor

DRUG

Pembrolizumab

PD-1 Inhibitor

Trial Locations (20)

8035

Hospital Universitari Vall d'Hebron, Barcelona

8908

Institut Catala d'Oncologia, Barcelona

20007

Georgetown, Washington D.C.

20132

Ospedale San Raffaele, Milan

21287

Johns Hopkins, Baltimore

28050

START Madrid-HM CIOCC, Madrid

36604

University of South Alabama, Mobile

37203

Sarah Cannon Research Institute at Tennessee Oncology, Nashville

37232

Vanderbilt, Nashville

48202

Henry Ford, Detroit

53100

Oncologica Azienda Ospedaliera Universitaria Senese, Siena

77230

MD Anderson, Houston

78229

START, San Antonio

85258

Honor Health/Pinnacle Oncology Hematology, Scottsdale

85719

University of Arizona, Tucson

02215

BIDMC, Boston

DFCI, Boston

77230-1402

MD Anderson, Houston

1066 CX

NKI, Amsterdam

HP 452

Radboudumc, Nijmegen